ArticleRespiratory research2026
Plasma metabolomic signatures associated with inhaled corticosteroid requirements in clinically stable asthma: a prospective cross-sectional study.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundDespite substantial clinical and biological heterogeneity, asthma severity is often classified by treatment intensity, which may inadequately reflect underlying pathobiology. We aimed to characterize plasma metabolomic profiles associated with treatment-defined severity among patients with clinically well-controlled asthma receiving guidance-based inhaled corticosteroid (ICS) therapy.
methodsIn this prospective cross-sectional study, patients with well-controlled asthma, defined by Asthma Control Test scores > 20 and consistent ICS use without recent exacerbations, were enrolled. Plasma samples were analyzed using proton nuclear magnetic resonance spectroscopy and liquid chromatography-mass spectrometry. After asthma severity was defined by ICS dose requirement, metabolomic differences were evaluated between severe and non-severe asthma. The significant metabolites were identified through elastic net-assisted variable selection and Firth's penalized logistic regression adjusting for clinical covariates. Probabilistic relationships among these metabolites and severity were further explored using Bayesian network modeling.
resultsFifty-five patients were included. Lactate and pyruvate levels were significantly elevated in the severe asthma group. In multivariable analyses adjusting for clinical covariates, pyruvate (adjusted odds ratio (aOR) = 10.239 [95% CI = 1.320-19480.301], P-value = 0.025) and dimethylamine (aOR = 12.693 [95% CI = 1.292-628.175], P-value = 0.028) were associated with treatment-defined severity. Bayesian network analysis further supported the direct probabilistic associations of these metabolites with asthma severity. Subgroup analyses confirmed consistent trends across clinical strata, suggesting that distinct metabolic states may underlie higher ICS requirements despite stable symptom control.
conclusionIn clinically stable asthma, elevated pyruvate and dimethylamine were associated with greater ICS requirements, suggesting that metabolomic profiling may aid in refining endotypes and personalizing anti-inflammatory therapy beyond symptom-based assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.